BACKGROUND: Sonic hedgehog (Shh) signaling plays a pivotal role in stromal-epithelial interaction during normal development but its role in tumor-stromal interaction during carcinogenic progression is less well defined. Since hormone refractory prostate cancer with bone metastasis is difficult to treat, it is crucial to investigate how androgen independent (AI) human prostate cancer cells communicate with their associated stroma. METHODS: Shh and its target transcription factor, Gli1 mRNA, were assessed by RT-PCR and/or quantitative RT-PCR in co-cultured cell recombinants comprised of AI C4-2 either with NPF (prostate fibroblasts from normal/benign prostate gland) or CPF (cancer-associated stromal fibroblasts) under Shh/cyclopamine (a hedgehog signaling inhibitor) treatment. Human bone marrow stromal (HS27A) cells were used as controls. In vivo investigation was performed by checking serum PSA and immunohistochemical staining for the apoptosis-associated M30 gene in mice bearing chimeric C4-2/NPF tumors. RESULTS: We found that (1) Shh has minimal growth-stimulating effects on prostate cancer cells, but it stimulated the growth of NPF but not CPF; (2) active Shh signaling was found between AI C4-2 cells and NPF but not CPF; and (3) osteonectin (ON) is a Gli1 target gene in NPF and not in CPF, and ON up-regulation in NPF can be blocked by cyclopamine CONCLUSIONS: Based on co-culture and chimeric tumor models, active Shh-mediated signaling was demonstrated between AI prostate cancer and NPF in a paracrine- and tumor progression-dependent manner. Our study suggests that drugs like cyclopamine that interfere with Shh signaling could be beneficial in preventing AI progression in prostate cancer cells.
BACKGROUND:Sonic hedgehog (Shh) signaling plays a pivotal role in stromal-epithelial interaction during normal development but its role in tumor-stromal interaction during carcinogenic progression is less well defined. Since hormone refractory prostate cancer with bone metastasis is difficult to treat, it is crucial to investigate how androgen independent (AI) human prostate cancer cells communicate with their associated stroma. METHODS:Shh and its target transcription factor, Gli1 mRNA, were assessed by RT-PCR and/or quantitative RT-PCR in co-cultured cell recombinants comprised of AI C4-2 either with NPF (prostate fibroblasts from normal/benign prostate gland) or CPF (cancer-associated stromal fibroblasts) under Shh/cyclopamine (a hedgehog signaling inhibitor) treatment. Human bone marrow stromal (HS27A) cells were used as controls. In vivo investigation was performed by checking serum PSA and immunohistochemical staining for the apoptosis-associated M30 gene in mice bearing chimeric C4-2/NPF tumors. RESULTS: We found that (1) Shh has minimal growth-stimulating effects on prostate cancer cells, but it stimulated the growth of NPF but not CPF; (2) active Shh signaling was found between AI C4-2 cells and NPF but not CPF; and (3) osteonectin (ON) is a Gli1 target gene in NPF and not in CPF, and ON up-regulation in NPF can be blocked by cyclopamine CONCLUSIONS: Based on co-culture and chimeric tumor models, active Shh-mediated signaling was demonstrated between AI prostate cancer and NPF in a paracrine- and tumor progression-dependent manner. Our study suggests that drugs like cyclopamine that interfere with Shh signaling could be beneficial in preventing AI progression in prostate cancer cells.
Authors: T J Bos; S L Cohn; H K Kleinman; J E Murphy-Ulrich; O L Podhajcer; S A Rempel; J N Rich; J T Rutka; E H Sage; E W Thompson Journal: Matrix Biol Date: 2004-04 Impact factor: 11.583
Authors: Wen-Chin Huang; Zhihui Xie; Hiroyuki Konaka; Jaro Sodek; Haiyen E Zhau; Leland W K Chung Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Ruoxiang Wang; Jianchun Xu; Lisa Juliette; Agapito Castilleja; John Love; Shian-Ying Sung; Haiyen E Zhau; Thomas J Goodwin; Leland W K Chung Journal: Semin Cancer Biol Date: 2005-10 Impact factor: 15.707
Authors: Jennifer E Koblinski; Benjamin R Kaplan-Singer; Sherilyn J VanOsdol; Michael Wu; Jean A Engbring; Songlin Wang; Corinne M Goldsmith; John T Piper; Jaroslav G Vostal; John F Harms; Danny R Welch; Hynda K Kleinman Journal: Cancer Res Date: 2005-08-15 Impact factor: 12.701
Authors: Leland W K Chung; Chia Ling Hsieh; Andrew Law; Shian Ying Sung; Thomas A Gardner; Masayuki Egawa; Shigeji Matsubara; Haiyen E Zhau Journal: Urology Date: 2003-11 Impact factor: 2.649
Authors: David M Berman; Nishita Desai; Xi Wang; Sunil S Karhadkar; Melissa Reynon; Cory Abate-Shen; Philip A Beachy; Michael M Shen Journal: Dev Biol Date: 2004-03-15 Impact factor: 3.582
Authors: Ginny L Powers; Kimberly D P Hammer; Maribella Domenech; Katsiaryna Frantskevich; Rita L Malinowski; Wade Bushman; David J Beebe; Paul C Marker Journal: Mol Cancer Res Date: 2014-08-22 Impact factor: 5.852
Authors: A A Farooqi; S Mukhtar; A M Riaz; S Waseem; S Minhaj; B A Dilawar; B A Malik; A Nawaz; S Bhatti Journal: Cell Prolif Date: 2011-10-04 Impact factor: 6.831
Authors: C D'Amato; R Rosa; R Marciano; V D'Amato; L Formisano; L Nappi; L Raimondo; C Di Mauro; A Servetto; F Fulciniti; A Cipolletta; C Bianco; F Ciardiello; B M Veneziani; S De Placido; R Bianco Journal: Br J Cancer Date: 2014-08-05 Impact factor: 7.640